Adaptimmune Therapeutics plc held its annual general meeting on May 29, 2025. During the meeting, several proposals were put to a vote. The re-appointment of KPMG LLP as auditors until the next annual general meeting was approved. The authorization for the Audit Committee to determine the auditors' remuneration for the fiscal year ending December 31, 2025, was also approved. Additionally, the adoption of the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2024, with no dividend recommended for that year, was approved.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。